{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T03:01:21Z","timestamp":1774321281043,"version":"3.50.1"},"reference-count":277,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Oncol"],"DOI":"10.3892\/ijo.2024.5628","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T07:35:05Z","timestamp":1708587305000},"source":"Crossref","is-referenced-by-count":12,"title":["Chimeric antigen receptor T cells in the treatment of osteosarcoma (Review)"],"prefix":"10.3892","volume":"64","author":[{"given":"Tong","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Orthopedics, The Second Norman Bethune Hospital of Jilin University, Changchun, Jilin 130000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weibo","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, The Second Norman Bethune Hospital of Jilin University, Changchun, Jilin 130000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, The Second Norman Bethune Hospital of Jilin University, Changchun, Jilin 130000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Operating Room, The Third Hospital of Qinhuangdao, Qinhuangdao, Hebei 066000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhang","family":"Jiao","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, The Second Norman Bethune Hospital of Jilin University, Changchun, Jilin 130000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minfei","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, The Second Norman Bethune Hospital of Jilin University, Changchun, Jilin 130000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"key":"key20240314101459_b1-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1051\/sicotj\/2017028","article-title":"Osteosarcoma: A comprehensive review","volume":"4","author":"Misaghi","year":"2018","journal-title":"SICOT J"},{"issue":"1 Suppl","key":"key20240314101459_b2-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"S203","DOI":"10.1002\/1097-0142(19950101)75:1+<203::AID-CNCR2820751308>3.0.CO;2-V","article-title":"Bone cancers","volume":"75","author":"Dorfman","year":"1995","journal-title":"Cancer"},{"key":"key20240314101459_b3-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1200\/JCO.2014.59.4895","article-title":"Osteosarcoma: Current treatment and a collaborative pathway to success","volume":"33","author":"Isakoff","year":"2015","journal-title":"J Clin Oncol"},{"key":"key20240314101459_b4-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.3390\/cancers12071899","article-title":"Impact of chemotherapy in the adjuvant setting of early stage uterine leiomyosarcoma: A systematic review and updated meta-analysis","volume":"12","author":"Rizzo","year":"2020","journal-title":"Cancers (Basel)"},{"key":"key20240314101459_b5-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"6322","DOI":"10.1038\/s41467-020-20059-6","article-title":"Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma","volume":"11","author":"Zhou","year":"2020","journal-title":"Nat Commun"},{"key":"key20240314101459_b6-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.12998\/wjcc.v7.i14.1753","article-title":"Current status of the adjuvant therapy in uterine sarcoma: A literature review","volume":"7","author":"Rizzo","year":"2019","journal-title":"World J Clin Cases"},{"key":"key20240314101459_b7-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"103596","DOI":"10.1016\/j.critrevonc.2022.103596","article-title":"The impact of gender on the efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study","volume":"170","author":"Santoni","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20240314101459_b8-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"6577","DOI":"10.4049\/jimmunol.151.11.6577","article-title":"Targeting of T lymphocytes to Neu\/HER2-expressing cells using chimeric single chain Fv receptors","volume":"151","author":"Stancovski","year":"1993","journal-title":"J Immunol"},{"key":"key20240314101459_b9-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"key20240314101459_b10-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.21037\/atm-20-4502","article-title":"Challenges and strategies of clinical application of CAR-T therapy in the treatment of tumors-a narrative review","volume":"8","author":"Li","year":"2020","journal-title":"Ann Transl Med"},{"key":"key20240314101459_b11-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1080\/17441692.2020.1825769","article-title":"Strategic use of patent opposition safeguard to improve equitable access to innovative health technologies: A case study of CAR T-cell therapy Kymriah","volume":"17","author":"Abbas","year":"2022","journal-title":"Glob Public Health"},{"key":"key20240314101459_b12-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.3390\/cancers12082126","article-title":"Genomic database analysis of uterine leiomyosarcoma mutational profile","volume":"12","author":"Astolfi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"key20240314101459_b13-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"key20240314101459_b14-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat Med"},{"key":"key20240314101459_b15-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"key20240314101459_b16-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"e127684","DOI":"10.1172\/jci.insight.127684","article-title":"Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma","volume":"4","author":"Garfall","year":"2018","journal-title":"JCI Insight"},{"key":"key20240314101459_b17-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jocit.2014.11.001","article-title":"CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma","volume":"2","author":"Guo","year":"2016","journal-title":"J Cell Immunother"},{"key":"key20240314101459_b18-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jcyt.2021.12.010","article-title":"CAR T targets and microenvironmental barriers of osteosarcoma","volume":"24","author":"Zhu","year":"2022","journal-title":"Cytotherapy"},{"key":"key20240314101459_b19-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.3390\/jcm11082158","article-title":"Development of CAR T cell therapy in children-A comprehensive overview","volume":"11","author":"Boettcher","year":"2022","journal-title":"J Clin Med"},{"key":"key20240314101459_b20-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discv"},{"key":"key20240314101459_b21-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/cas.12362","article-title":"Heat shock protein DNAJB8 is a novel target for immunotherapy of colon cancer-initiating cells","volume":"105","author":"Morita","year":"2014","journal-title":"Cancer Sci"},{"key":"key20240314101459_b22-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J Clin Oncol"},{"key":"key20240314101459_b23-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-15-2428","article-title":"Molecular pathways: Targeting B7-H3 (CD276) for human cancer immunotherapy","volume":"22","author":"Picarda","year":"2016","journal-title":"Clin Cancer Res"},{"key":"key20240314101459_b24-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13046-019-1147-6","article-title":"Anti-CD166\/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma","volume":"38","author":"Wang","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"key20240314101459_b25-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41417-020-00221-4","article-title":"Chimeric antigen receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours","volume":"28","author":"Hsu","year":"2021","journal-title":"Cancer Gene Ther"},{"key":"key20240314101459_b26-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"e003897","DOI":"10.1136\/jitc-2021-003897","article-title":"Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer","volume":"10","author":"Reppel","year":"2022","journal-title":"J Immunother Cancer"},{"key":"key20240314101459_b27-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1158\/0008-5472.CAN-11-2778","article-title":"Genetically modified T cells targeting interleukin-11 receptor \u03b1-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases","volume":"72","author":"Huang","year":"2012","journal-title":"Cancer Res"},{"key":"key20240314101459_b28-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"e0133152","DOI":"10.1371\/journal.pone.0133152","article-title":"IGF1R- and ROR1-specific CAR T cells as a potential therapy for high risk sarcomas","volume":"10","author":"Huang","year":"2015","journal-title":"PLoS One"},{"key":"key20240314101459_b29-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"5824","DOI":"10.1158\/1078-0432.CCR-17-0075","article-title":"Memory T cells expressing an NKG2D-CAR efficiently target osteosarcoma cells","volume":"23","author":"Fern\u00e1ndez","year":"2017","journal-title":"Clin Cancer Res"},{"key":"key20240314101459_b30-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1758835919855491","DOI":"10.1177\/1758835919855491","article-title":"Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma","volume":"11","author":"Riccardo","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"key20240314101459_b31-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s13018-015-0328-z","article-title":"Prognostic significance of CD44V6 expression in osteosarcoma: A meta-analysis","volume":"10","author":"Zhang","year":"2015","journal-title":"J Orthop Surg Res"},{"key":"key20240314101459_b32-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"4469","DOI":"10.3390\/cancers13174469","article-title":"Chimeric antigen receptor T-cell therapy: The light of day for osteosarcoma","volume":"13","author":"Lin","year":"2021","journal-title":"Cancers (Basel)"},{"key":"key20240314101459_b33-ijo-64-04-05628","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"key20240314101459_b34-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jbo.2017.10.002","article-title":"Inhibition of IL-18-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy against osteosarcoma cancer","volume":"9","author":"Guan","year":"2017","journal-title":"J Bone Oncol"},{"key":"key20240314101459_b35-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13045-018-0560-1","article-title":"PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse","volume":"11","author":"Zheng","year":"2018","journal-title":"J Hematol Oncol"},{"key":"key20240314101459_b36-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"3966","DOI":"10.1158\/1078-0432.CCR-08-0356","article-title":"Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers","volume":"14","author":"Wallace","year":"2008","journal-title":"Clin Cancer Res"},{"key":"key20240314101459_b37-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci Transl Med"},{"key":"key20240314101459_b38-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/ijms14010088","article-title":"The role of the VEGF-C\/VEGFRs axis in tumor progression and therapy","volume":"14","author":"Chen","year":"2012","journal-title":"Int J Mol Sci"},{"key":"key20240314101459_b39-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1016\/j.celrep.2018.04.051","article-title":"Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system","volume":"23","author":"Avanzi","year":"2018","journal-title":"Cell Rep"},{"key":"key20240314101459_b40-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1172\/JCI87624","article-title":"Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors","volume":"127","author":"Smith","year":"2017","journal-title":"J Clin Invest"},{"key":"key20240314101459_b41-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"6747","DOI":"10.1158\/0008-5472.CAN-16-1404","article-title":"Recurrent loss of STING signaling in melanoma correlates with susceptibility to viral oncolysis","volume":"76","author":"Xia","year":"2016","journal-title":"Cancer Res"},{"key":"key20240314101459_b42-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1016\/j.ymthe.2018.09.008","article-title":"Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape","volume":"26","author":"DeSelm","year":"2018","journal-title":"Mol Ther"},{"key":"key20240314101459_b43-ijo-64-04-05628","first-page":"674","article-title":"GD2 chimeric antigen receptor modified T cells in synergy with sub-toxic level of doxorubicin targeting osteosarcomas","volume":"10","author":"Chulanetra","year":"2020","journal-title":"Am J Cancer Res"},{"key":"key20240314101459_b44-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"204","DOI":"10.14735\/amko2016204","article-title":"Changes in the CD8+ density of tumor infiltrating lymphocytes after neoadjuvant radiochemotherapy in patients with rectal adenocarcinom","volume":"29","author":"Buka","year":"2016","journal-title":"Klin Onkol"},{"key":"key20240314101459_b45-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"212567","DOI":"10.7573\/dic.212567","article-title":"Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: Opportunities and challenges","volume":"8","author":"Makita","year":"2019","journal-title":"Drugs Context"},{"key":"key20240314101459_b46-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"927153","DOI":"10.3389\/fimmu.2022.927153","article-title":"CAR-T cell therapy in hematological malignancies: Current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"key20240314101459_b47-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1063454","DOI":"10.3389\/fimmu.2023.1063454","article-title":"Analysis of causes for poor persistence of CAR-T cell therapy in vivo","volume":"14","author":"Kong","year":"2023","journal-title":"Front Immunol"},{"key":"key20240314101459_b48-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"2114254","DOI":"10.1080\/21645515.2022.2114254","article-title":"Current updates on generations, approvals, and clinical trials of CAR T-cell therapy","volume":"18","author":"Asmamaw Dejenie","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"key20240314101459_b49-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","article-title":"Cancer immunotherapy: The beginning of the end of cancer?","volume":"14","author":"Farkona","year":"2016","journal-title":"BMC Med"},{"key":"key20240314101459_b50-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.nrl.2010.10.005","article-title":"Anticuerpos monoclonales. Aspectos b\u00e1sicos","volume":"26","author":"Garc\u00eda Merino","year":"2011","journal-title":"Neurolog\u00eda"},{"key":"key20240314101459_b51-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3892\/ijo.2022.5302","article-title":"Retrospective analysis of the preparation and application of immunotherapy in cancer treatment (review)","volume":"60","author":"Lu","year":"2022","journal-title":"Int J Oncol"},{"key":"key20240314101459_b52-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/mt.2009.133","article-title":"Immunotherapy for osteosarcoma: Genetic modification of T cells overcomes low levels of tumor antigen expression","volume":"17","author":"Ahmed","year":"2009","journal-title":"Mol Ther"},{"key":"key20240314101459_b53-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.ymthe.2005.04.016","article-title":"A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells","volume":"12","author":"Pul\u00e8","year":"2005","journal-title":"Mol Ther"},{"key":"key20240314101459_b54-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/tan.12113","article-title":"Preferential expression of cancer\/testis genes in cancer stem-like cells: Proposal of a novel sub-category, cancer\/testis\/stem gene","volume":"81","author":"Yamada","year":"2013","journal-title":"Tissue Antigens"},{"key":"key20240314101459_b55-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1158\/0008-5472.CAN-11-3062","article-title":"HSP DNAJB8 controls tumor-initiating ability in renal cancer stem-like cells","volume":"72","author":"Nishizawa","year":"2012","journal-title":"Cancer Res"},{"key":"key20240314101459_b56-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/s41416-022-02100-1","article-title":"Development of CAR-T cells specifically targeting cancer stem cell antigen DNAJB8 against solid tumours","volume":"128","author":"Watanabe","year":"2023","journal-title":"Br J Cancer"},{"key":"key20240314101459_b57-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"key20240314101459_b58-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/PAI.0000000000000197","article-title":"The prognostic role of Ezrin and HER2\/neu expression in osteosarcoma","volume":"24","author":"Abdou","year":"2016","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"key20240314101459_b59-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"101138","DOI":"10.1016\/j.tranon.2021.101138","article-title":"Targeting CD276 by CAR-T cells induces regression of esophagus squamous cell carcinoma in xenograft mouse models","volume":"14","author":"Xuan","year":"2021","journal-title":"Transl Oncol"},{"key":"key20240314101459_b60-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1158\/1535-7163.MCT-20-0446","article-title":"Targeting radiation-resistant prostate cancer stem cells by B7-H3 CAR T cells","volume":"20","author":"Zhang","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"key20240314101459_b61-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ccell.2019.01.002","article-title":"Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells","volume":"35","author":"Du","year":"2019","journal-title":"Cancer Cell"},{"key":"key20240314101459_b62-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41591-020-0821-8","article-title":"Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid\/rhabdoid tumors","volume":"26","author":"Theruvath","year":"2020","journal-title":"Nat Med"},{"key":"key20240314101459_b63-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"691741","DOI":"10.3389\/fimmu.2021.691741","article-title":"A novel orthotopic implantation technique for osteosarcoma produces spontaneous metastases and illustrates dose-dependent efficacy of B7-H3-CAR T cells","volume":"12","author":"Talbot","year":"2021","journal-title":"Front Immunol"},{"key":"key20240314101459_b64-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","article-title":"CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors","volume":"25","author":"Majzner","year":"2019","journal-title":"Clin Cancer Res"},{"key":"key20240314101459_b65-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1078\/0171-9335-00256","article-title":"Activated leukocyte cell adhesion molecule (CD166\/ALCAM): Developmental and mechanistic aspects of cell clustering and cell migration","volume":"81","author":"Swart","year":"2002","journal-title":"Eur J Cell Biol"},{"key":"key20240314101459_b66-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"126906","DOI":"10.1155\/2012\/126906","article-title":"Enhanced growth inhibition of osteosarcoma by cytotoxic polymerized liposomal nanoparticles targeting the alcam cell surface receptor","volume":"2012","author":"Federman","year":"2012","journal-title":"Sarcoma"},{"key":"key20240314101459_b67-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"101575","DOI":"10.1016\/j.tranon.2022.101575","article-title":"CD166-specific CAR-T cells potently target colorectal cancer cells","volume":"27","author":"He","year":"2023","journal-title":"Transl Oncol"},{"key":"key20240314101459_b68-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"rs13","DOI":"10.1126\/scisignal.2003624","article-title":"Simultaneous profiling of 194 distinct receptor transcripts in human cells","volume":"6","author":"Kang","year":"2013","journal-title":"Sci Signal"},{"key":"key20240314101459_b69-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/nrc2806","article-title":"Eph receptors and ephrins in cancer: Bidirectional signalling and beyond","volume":"10","author":"Pasquale","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"key20240314101459_b70-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1158\/1541-7786.MCR-08-0244","article-title":"The EphA2 receptor and ephrinA1 ligand in solid tumors: Function and therapeutic targeting","volume":"6","author":"Wykosky","year":"2008","journal-title":"Mol Cancer Res"},{"key":"key20240314101459_b71-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/j.1365-2559.2010.03713.x","article-title":"De novo expression of EphA2 in osteosarcoma modulates activation of the mitogenic signalling pathway","volume":"57","author":"Fritsche-Guenther","year":"2010","journal-title":"Histopathology"},{"key":"key20240314101459_b72-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/1471-2407-14-295","article-title":"Ganglioside GD2 in reception and transduction of cell death signal in tumor cells","volume":"14","author":"Doronin","year":"2014","journal-title":"BMC Cancer"},{"key":"key20240314101459_b73-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/cncr.28461","article-title":"Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma","volume":"120","author":"Roth","year":"2014","journal-title":"Cancer"},{"key":"key20240314101459_b74-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1158\/2326-6066.CIR-15-0230","article-title":"Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas","volume":"4","author":"Long","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"key20240314101459_b75-ijo-64-04-05628","first-page":"e18349","article-title":"A deep dive into the newest avenues of immunotherapy for pediatric osteosarcoma: A systematic review","volume":"13","author":"Suri","year":"2021","journal-title":"Cureus"},{"key":"key20240314101459_b76-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13045-020-01012-y","article-title":"GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma","volume":"13","author":"Park","year":"2020","journal-title":"J Hematol Oncol"},{"key":"key20240314101459_b77-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jconrel.2022.08.048","article-title":"IL-11R\u03b1-targeted nanostrategy empowers chemotherapy of relapsed and patient-derived osteosarcoma","volume":"350","author":"Jiang","year":"2022","journal-title":"J Control Release"},{"key":"key20240314101459_b78-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00292-020-00756-1","article-title":"The role of interleukin-11 in osteosarcoma","volume":"41","author":"Lokau","year":"2020","journal-title":"Der Pathologe"},{"key":"key20240314101459_b79-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.currproblcancer.2018.08.008","article-title":"The possible role of insulin-like growth factor-1 in osteosarcoma","volume":"43","author":"Li","year":"2019","journal-title":"Curr Probl Cancer"},{"key":"key20240314101459_b80-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1158\/1535-7163.MCT-09-0115","article-title":"Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines","volume":"8","author":"Duan","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"key20240314101459_b81-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"15033","DOI":"10.1038\/boneres.2015.33","article-title":"MicroRNA-26a inhibits osteosarcoma cell proliferation by targeting IGF-1","volume":"3","author":"Tan","year":"2015","journal-title":"Bone Res"},{"key":"key20240314101459_b82-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"NP40","DOI":"10.1177\/1533034615601281","article-title":"MiR-100 inhibits osteosarcoma cell proliferation, migration, and invasion and enhances chemosensitivity by targeting IGFIR","volume":"15","author":"Liu","year":"2016","journal-title":"Technol Cancer Res Treat"},{"key":"key20240314101459_b83-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1159\/000438653","article-title":"MicroRNA-133a inhibits osteosarcoma cells proliferation and invasion via targeting IGF-1R","volume":"38","author":"Chen","year":"2016","journal-title":"Cell Physiol Biochem"},{"key":"key20240314101459_b84-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.semcancer.2014.07.005","article-title":"The receptor tyrosine kinase ROR1-an oncofetal antigen for targeted cancer therapy","volume":"29","author":"Hojjat-Farsangi","year":"2014","journal-title":"Semin Cancer Biol"},{"key":"key20240314101459_b85-ijo-64-04-05628","first-page":"601","article-title":"Wnt5a\/ROR1 activates DAAM1 and promotes the migration in osteosarcoma cells","volume":"43","author":"Dai","year":"2020","journal-title":"Oncol Rep"},{"key":"key20240314101459_b86-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"5927","DOI":"10.1158\/0008-5472.CAN-06-0130","article-title":"Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor","volume":"66","author":"Zhang","year":"2006","journal-title":"Cancer Res"},{"key":"key20240314101459_b87-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3390\/ijms19010177","article-title":"Fusion proteins of NKG2D\/NKG2DL in cancer immunotherapy","volume":"19","author":"Ding","year":"2018","journal-title":"Int J Mol Sci"},{"key":"key20240314101459_b88-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"key20240314101459_b89-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00280-018-3670-0","article-title":"Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment","volume":"82","author":"Tao","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20240314101459_b90-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"110562","DOI":"10.1016\/j.biopha.2020.110562","article-title":"Novel cellular immunotherapy using NKG2D CAR-T for the treatment of cervical cancer","volume":"131","author":"Zhang","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"key20240314101459_b91-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1158\/2326-6066.CIR-19-0026","article-title":"Eradication of hepatocellular carcinoma by NKG2D-based CAR-T cells","volume":"7","author":"Sun","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"key20240314101459_b92-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2174\/156652410791316977","article-title":"CSPG4 in cancer: multiple roles","volume":"10","author":"Wang","year":"2010","journal-title":"Curr Mol Med"},{"key":"key20240314101459_b93-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12967-017-1250-4","article-title":"CSPG4: A prototype oncoantigen for translational immunotherapy studies","volume":"15","author":"Rolih","year":"2017","journal-title":"J Transl Med"},{"key":"key20240314101459_b94-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"6075","DOI":"10.3390\/cancers13236075","article-title":"Tumor-infiltrating lymphocytes and cancer markers in osteosarcoma: Influence on patient survival","volume":"13","author":"Casanova","year":"2021","journal-title":"Cancers (Basel)"},{"key":"key20240314101459_b95-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"496193","DOI":"10.1155\/2013\/496193","article-title":"The prognostic significance of CD44V6, CDH11, and \u03b2-catenin expression in patients with osteosarcoma","volume":"2013","author":"Deng","year":"2013","journal-title":"Biomed Res Int"},{"key":"key20240314101459_b96-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.2147\/OTT.S156101","article-title":"Prognostic value of CD44v6 expression in breast cancer: A meta-analysis","volume":"11","author":"Qiao","year":"2018","journal-title":"Onco Targets Ther"},{"key":"key20240314101459_b97-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.3892\/or.2013.2273","article-title":"CD44v6 expression is related to mesenchymal phenotype and poor prognosis in patients with colorectal cancer","volume":"29","author":"Saito","year":"2013","journal-title":"Oncol Rep"},{"key":"key20240314101459_b98-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1292\/jvms.10-0002","article-title":"Expression of CD44v6 as matrix-associated ectodomain in the bone development","volume":"72","author":"Nakajima","year":"2010","journal-title":"J Vet Med Sci"},{"key":"key20240314101459_b99-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.7150\/ijbs.34213","article-title":"Current progress in CAR-T cell therapy for solid tumors","volume":"15","author":"Ma","year":"2019","journal-title":"Int J Biol Sci"},{"key":"key20240314101459_b100-ijo-64-04-05628","first-page":"228","article-title":"Target selection of CAR T cell therapy in accordance with the TME for solid tumors","volume":"9","author":"Liu","year":"2019","journal-title":"Am J Cancer Res"},{"key":"key20240314101459_b101-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"6125","DOI":"10.4049\/jimmunol.173.10.6125","article-title":"Expression and characterization of a novel CD6 ligand in cells derived from joint and epithelial tissues","volume":"173","author":"Saifullah","year":"2004","journal-title":"J Immunol"},{"key":"key20240314101459_b102-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"55315","DOI":"10.1074\/jbc.M407776200","article-title":"Molecular isolation and characterization of a soluble isoform of activated leukocyte cell adhesion molecule that modulates endothelial cell function","volume":"279","author":"Ikeda","year":"2004","journal-title":"J Biol Chem"},{"key":"key20240314101459_b103-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1186\/s12885-022-10229-8","article-title":"B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Cancer"},{"key":"key20240314101459_b104-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.ccell.2017.03.002","article-title":"Harnessing the immunotherapy revolution for the treatment of childhood cancers","volume":"31","author":"Majzner","year":"2017","journal-title":"Cancer Cell"},{"key":"key20240314101459_b105-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ymthe.2016.10.016","article-title":"Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer","volume":"25","author":"Mohammed","year":"2017","journal-title":"Mol Ther"},{"key":"key20240314101459_b106-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccell.2017.02.008","article-title":"Obstacles posed by the tumor microenvironment to T cell activity: A case for synergistic therapies","volume":"31","author":"Anderson","year":"2017","journal-title":"Cancer Cell"},{"key":"key20240314101459_b107-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"key20240314101459_b108-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.2147\/OTT.S124008","article-title":"Targeting the PD-1 pathway in pediatric solid tumors and brain tumors","volume":"10","author":"Wagner","year":"2017","journal-title":"Onco Targets Ther"},{"key":"key20240314101459_b109-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"528","DOI":"10.3390\/diagnostics10080528","article-title":"Characterization of PD-1\/PD-L1 immune checkpoint expression in osteosarcoma","volume":"10","author":"Hashimoto","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"key20240314101459_b110-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3892\/or.2013.2224","article-title":"Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma","volume":"29","author":"Kawano","year":"2013","journal-title":"Oncol Rep"},{"key":"key20240314101459_b111-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40425-015-0067-z","article-title":"Combination immunotherapy with \u03b1-CTLA-4 and \u03b1-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma","volume":"3","author":"Lussier","year":"2015","journal-title":"J Immunother Cancer"},{"key":"key20240314101459_b112-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.21037\/atm-21-3928","article-title":"T cell exhaustion drives osteosarcoma pathogenesis","volume":"9","author":"Sun","year":"2021","journal-title":"Ann Transl Med"},{"key":"key20240314101459_b113-ijo-64-04-05628","first-page":"2009","article-title":"IFN\u03b3 and TNF\u03b1 synergistically promote galectin 9 secretion by human osteosarcoma cells MG-63 to prevent T cell killing","volume":"13","author":"Liu","year":"2020","journal-title":"Int J Clin Exp Pathol"},{"key":"key20240314101459_b114-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: Current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"key20240314101459_b115-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"key20240314101459_b116-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"799","DOI":"10.3390\/ijms24010799","article-title":"Strategies to overcome resistance to immune-based therapies in osteosarcoma","volume":"24","author":"Hattinger","year":"2023","journal-title":"Int J Mol Sci"},{"key":"key20240314101459_b117-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s13402-021-00598-w","article-title":"The role of tumor-associated macrophages in osteosarcoma progression-therapeutic implications","volume":"44","author":"Huang","year":"2021","journal-title":"Cell Oncol (Dordr)"},{"key":"key20240314101459_b118-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"78343","DOI":"10.18632\/oncotarget.13055","article-title":"Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma","volume":"7","author":"Dumars","year":"2016","journal-title":"Oncotarget"},{"key":"key20240314101459_b119-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/exd.14721","article-title":"Significance of regulatory T cells in cancer immunology and immunotherapy","volume":"32","author":"Sugiyama","year":"2023","journal-title":"Exp Dermatol"},{"key":"key20240314101459_b120-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1365-2567.2006.02321.x","article-title":"Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: The role of T regulatory cells","volume":"117","author":"Taylor","year":"2006","journal-title":"Immunology"},{"key":"key20240314101459_b121-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3390\/cells9030561","article-title":"Myeloid-derived suppressor cells as a therapeutic target for cancer","volume":"9","author":"Law","year":"2020","journal-title":"Cells"},{"key":"key20240314101459_b122-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s13277-013-1136-x","article-title":"Effect of the cytokine levels in serum on osteosarcoma","volume":"35","author":"Xiao","year":"2014","journal-title":"Tumor Biol"},{"key":"key20240314101459_b123-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"16155","DOI":"10.3390\/ijms232416155","article-title":"The role of tumor microenvironment in regulating the plasticity of osteosarcoma cells","volume":"23","author":"Tian","year":"2022","journal-title":"Int J Mol Sci"},{"key":"key20240314101459_b124-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-13-3191","article-title":"Overexpression of smad7 blocks primary tumor growth and lung metastasis development in osteosarcoma","volume":"20","author":"Lamora","year":"2014","journal-title":"Clin Cancer Res"},{"key":"key20240314101459_b125-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"9830","DOI":"10.1021\/acsnano.8b00967","article-title":"Local blockade of interleukin 10 and C-X-C motif chemokine ligand 12 with nano-delivery promotes antitumor response in murine cancers","volume":"12","author":"Shen","year":"2018","journal-title":"ACS Nano"},{"key":"key20240314101459_b126-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13046-018-0799-y","article-title":"Reprogramming the murine colon cancer microenvironment using lentivectors encoding shRNA against IL-10 as a component of a potent DC-based chemoimmunotherapy","volume":"37","author":"Rossowska","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"key20240314101459_b127-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.7150\/jca.37932","article-title":"Mesenchymal stem\/stromal cells-derived IL-6 promotes nasopharyngeal carcinoma growth and resistance to cisplatin via upregulating CD73 expression","volume":"11","author":"Zeng","year":"2020","journal-title":"J Cancer"},{"key":"key20240314101459_b128-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"6985","DOI":"10.3390\/ijms21196985","article-title":"Bone microenvironment and osteosarcoma metastasis","volume":"21","author":"Yang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"key20240314101459_b129-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"88","DOI":"10.2174\/1568009615666150126154151","article-title":"Involvement of mesenchymal stem cells in cancer progression and metastases","volume":"15","author":"Chang","year":"2015","journal-title":"Curr Cancer Drug Targets"},{"key":"key20240314101459_b130-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/1878-0261.12189","article-title":"Bone marrow-derived mesenchymal stem cells promote invasiveness and transendothelial migration of osteosarcoma cells via a mesenchymal to amoeboid transition","volume":"12","author":"Pietrovito","year":"2018","journal-title":"Mol Oncol"},{"key":"key20240314101459_b131-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","article-title":"Tumor angiogenesis: Causes, consequences, challenges and opportunities","volume":"77","author":"Lugano","year":"2020","journal-title":"Cell Mol Life Sci"},{"key":"key20240314101459_b132-ijo-64-04-05628","first-page":"163","article-title":"Mesenchymal stem cells promote tumor engraftment and metastatic colonization in rat osteosarcoma model","volume":"40","author":"Tsukamoto","year":"2012","journal-title":"Int J Oncol"},{"key":"key20240314101459_b133-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"e82934","DOI":"10.7554\/eLife.82934","article-title":"Mesenchymal stem cell suppresses the efficacy of CAR-T toward killing lymphoma cells by modulating the microenvironment through stanniocalcin-1","volume":"12","author":"Zhang","year":"2023","journal-title":"Elife"},{"key":"key20240314101459_b134-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1515\/med-2020-0180","article-title":"Hypoxia stimulates the migration and invasion of osteosarcoma via up-regulating the NUSAP1 expression","volume":"16","author":"Zhang","year":"2021","journal-title":"Open Med (Wars)"},{"key":"key20240314101459_b135-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.gendis.2016.11.003","article-title":"The role of hypoxia-inducible factors in tumor angiogenesis and cell metabolism","volume":"4","author":"Lv","year":"2016","journal-title":"Genes Dis"},{"key":"key20240314101459_b136-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.canlet.2014.11.034","article-title":"The HIF-1\u03b1\/CXCR4 pathway supports hypoxia-induced metastasis of human osteosarcoma cells","volume":"357","author":"Guan","year":"2015","journal-title":"Cancer Lett"},{"key":"key20240314101459_b137-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3727\/096504016X14562725373752","article-title":"MicroRNA-20b downregulates HIF-1\u03b1 and inhibits the proliferation and invasion of osteosarcoma cells","volume":"23","author":"Liu","year":"2016","journal-title":"Oncol Res"},{"key":"key20240314101459_b138-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"key20240314101459_b139-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.3389\/fonc.2019.01143","article-title":"Lactate in the regulation of tumor microenvironment and therapeutic approaches","volume":"9","author":"de la Cruz-L\u00f3pez","year":"2019","journal-title":"Front Oncol"},{"key":"key20240314101459_b140-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"100787","DOI":"10.1016\/j.drup.2021.100787","article-title":"Hypoxia as a driver of resistance to immunotherapy","volume":"59","author":"Kopecka","year":"2021","journal-title":"Drug Resist Updat"},{"key":"key20240314101459_b141-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1002\/ijc.30540","article-title":"Cancer-associated mesenchymal stroma fosters the stemness of osteosarcoma cells in response to intratumoral acidosis via NF-\u03baB activation","volume":"140","author":"Avnet","year":"2017","journal-title":"Int J Cancer"},{"key":"key20240314101459_b142-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1097\/01.mnh.0000174146.52915.5d","article-title":"Na+\/H+ exchangers: Physiology and link to hypertension and organ ischemia","volume":"14","author":"Bobulescu","year":"2005","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"key20240314101459_b143-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s10555-007-9064-0","article-title":"Regulation of tumor pH and the role of carbonic anhydrase 9","volume":"26","author":"Swietach","year":"2007","journal-title":"Cancer Metastasis Rev"},{"key":"key20240314101459_b144-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/j.1582-4934.2009.00994.x","article-title":"Tumor hypoxia induces a metabolic shift causing acidosis: A common feature in cancer","volume":"14","author":"Chiche","year":"2010","journal-title":"J Cell Mol Med"},{"key":"key20240314101459_b145-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.7150\/ijms.74137","article-title":"Role of extracellular vesicles in osteosarcoma","volume":"19","author":"Yang","year":"2022","journal-title":"Int J Med Sci"},{"key":"key20240314101459_b146-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2020.12.024","article-title":"Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs","volume":"500","author":"Chen","year":"2021","journal-title":"Cancer Lett"},{"key":"key20240314101459_b147-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3390\/cancers13010083","article-title":"Recent insights into therapy resistance in osteosarcoma","volume":"13","author":"Prudowsky","year":"2020","journal-title":"Cancers (Basel)"},{"key":"key20240314101459_b148-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"4927","DOI":"10.1038\/srep04927","article-title":"Beyond Warburg effect-dual metabolic nature of cancer cells","volume":"4","author":"Xie","year":"2014","journal-title":"Sci Rep"},{"key":"key20240314101459_b149-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1139\/bcb-2021-0305","article-title":"PDGFR\u03b2 modulates aerobic glycolysis in osteosarcoma HOS cells via the PI3K\/AKT\/mTOR\/c-Myc pathway","volume":"100","author":"Tang","year":"2022","journal-title":"Biochem Cell Biol"},{"key":"key20240314101459_b150-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1158\/0008-5472.CAN-04-4505","article-title":"Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: A mechanism of tumor evasion","volume":"65","author":"Zea","year":"2005","journal-title":"Cancer Res"},{"key":"key20240314101459_b151-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1600-065X.2008.00608.x","article-title":"Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: Mechanisms and therapeutic perspectives","volume":"222","author":"Rodr\u00edguez","year":"2008","journal-title":"Immunol Rev"},{"key":"key20240314101459_b152-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12967-020-02667-4","article-title":"Hypoxia and the phenomenon of immune exclusion","volume":"19","author":"Pietrobon","year":"2021","journal-title":"J Transl Med"},{"key":"key20240314101459_b153-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.coi.2017.04.006","article-title":"Targeting T cell metabolism to regulate T cell activation, differentiation and function in disease","volume":"46","author":"Patel","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"key20240314101459_b154-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann Oncol"},{"key":"key20240314101459_b155-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"5474602","DOI":"10.1155\/2016\/5474602","article-title":"CAR T cell therapy: A game changer in cancer treatment","volume":"2016","author":"Alm\u00e5sbak","year":"2016","journal-title":"J Immunol Res"},{"key":"key20240314101459_b156-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody-modified T cells: CARs take the front seat for hematologic malignancies","volume":"123","author":"Maus","year":"2014","journal-title":"Blood"},{"key":"key20240314101459_b157-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","article-title":"NR4A transcription factors limit CAR T cell function in solid tumours","volume":"567","author":"Chen","year":"2019","journal-title":"Nature"},{"key":"key20240314101459_b158-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1097\/CJI.0b013e31827806e6","article-title":"Sorting through subsets: Which T-cell populations mediate highly effective adoptive immunotherapy?","volume":"35","author":"Klebanoff","year":"2012","journal-title":"J Immunother"},{"key":"key20240314101459_b159-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s11427-016-5027-4","article-title":"Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors","volume":"59","author":"Zhang","year":"2016","journal-title":"Sci China Life Sci"},{"key":"key20240314101459_b160-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1089\/10430340260355374","article-title":"Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2","volume":"13","author":"Kershaw","year":"2002","journal-title":"Hum Gene Ther"},{"key":"key20240314101459_b161-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-15-0224","article-title":"Targeting YAP-dependent MDSC infiltration impairs tumor progression","volume":"6","author":"Wang","year":"2016","journal-title":"Cancer Discov"},{"key":"key20240314101459_b162-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20240314101459_b163-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"90521","DOI":"10.18632\/oncotarget.19361","article-title":"Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: Challenges and opportunities","volume":"8","author":"Xia","year":"2017","journal-title":"Oncotarget"},{"key":"key20240314101459_b164-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"e155621","DOI":"10.1172\/JCI155621","article-title":"An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma","volume":"132","author":"Tian","year":"2022","journal-title":"J Clin Invest"},{"key":"key20240314101459_b165-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.omto.2022.02.012","article-title":"A novel TanCAR targeting IL13R\u03b12 and EphA2 for enhanced glioblastoma therapy","volume":"24","author":"Muhammad","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"key20240314101459_b166-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13045-019-0813-7","article-title":"Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy","volume":"12","author":"Han","year":"2019","journal-title":"J Hematol Oncol"},{"key":"key20240314101459_b167-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1158\/2326-6066.CIR-14-0127","article-title":"The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity","volume":"3","author":"Hudecek","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"key20240314101459_b168-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","article-title":"Engineering CAR-T cells: Design concepts","volume":"36","author":"Srivastava","year":"2015","journal-title":"Trends Immunol"},{"key":"key20240314101459_b169-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1158\/2326-6066.CIR-14-0200","article-title":"Functional tuning of CARs reveals signaling threshold above which CD8+ CTL antitumor potency is attenuated due to cell fas-FasL-dependent AICD","volume":"3","author":"K\u00fcnkele","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"key20240314101459_b170-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"7028","DOI":"10.4049\/jimmunol.180.10.7028","article-title":"Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane","volume":"180","author":"James","year":"2008","journal-title":"J Immunol"},{"key":"key20240314101459_b171-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.4049\/jimmunol.180.7.4901","article-title":"Retargeting of human T cells to tumor-associated MUC1: The evolution of a chimeric antigen receptor","volume":"180","author":"Wilkie","year":"2008","journal-title":"J Immunol"},{"key":"key20240314101459_b172-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1158\/1078-0432.CCR-13-0330","article-title":"Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells","volume":"19","author":"Hudecek","year":"2013","journal-title":"Clin Cancer Res"},{"key":"key20240314101459_b173-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/01.cji.0000161397.96582.59","article-title":"The role of extracellular spacer regions in the optimal design of chimeric immune receptors: Evaluation of four different scFvs and antigens","volume":"28","author":"Guest","year":"2005","journal-title":"J Immunother"},{"key":"key20240314101459_b174-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-019-0737-3","article-title":"Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma","volume":"26","author":"Brudno","year":"2020","journal-title":"Nat Med"},{"key":"key20240314101459_b175-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","article-title":"Function of novel Anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains","volume":"25","author":"Alabanza","year":"2017","journal-title":"Mol Ther"},{"key":"key20240314101459_b176-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/gt.2010.91","article-title":"Adoptive immunotherapy with genetically engineered T cells: Modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response","volume":"17","author":"Hombach","year":"2010","journal-title":"Gene Ther"},{"key":"key20240314101459_b177-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/gt.2015.4","article-title":"Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model","volume":"22","author":"Alm\u00e5sbak","year":"2015","journal-title":"Gene Ther"},{"key":"key20240314101459_b178-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"e1253656","DOI":"10.1080\/2162402X.2016.1253656","article-title":"Fine-tuning the CAR spacer improves T-cell potency","volume":"5","author":"Watanabe","year":"2016","journal-title":"Oncoimmunology"},{"key":"key20240314101459_b179-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3390\/cells8050472","article-title":"Limitations in the design of chimeric antigen receptors for cancer therapy","volume":"8","author":"Stoiber","year":"2019","journal-title":"Cells"},{"key":"key20240314101459_b180-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"6938","DOI":"10.4049\/jimmunol.0901766","article-title":"The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR\/CD3 complex","volume":"184","author":"Bridgeman","year":"2010","journal-title":"J Immunol"},{"key":"key20240314101459_b181-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"e96976","DOI":"10.1172\/jci.insight.96976","article-title":"Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation","volume":"3","author":"Guedan","year":"2018","journal-title":"JCI Insight"},{"key":"key20240314101459_b182-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41423-018-0183-z","article-title":"Transmembrane domain-mediated Lck association underlies bystander and costimulatory ICOS signaling","volume":"17","author":"Wan","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"key20240314101459_b183-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the antigen density requirement for CAR T-cell activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov"},{"key":"key20240314101459_b184-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.3390\/cells9051182","article-title":"Hinge and transmembrane domains of chimeric antigen receptor regulate receptor expression and signaling threshold","volume":"9","author":"Fujiwara","year":"2020","journal-title":"Cells"},{"key":"key20240314101459_b185-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: A single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol"},{"key":"key20240314101459_b186-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-020-00910-5","article-title":"Recent advances in CAR-T cell engineering","volume":"13","author":"Huang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"key20240314101459_b187-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"key":"key20240314101459_b188-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1182\/blood-2011-03-344275","article-title":"CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo","volume":"119","author":"Song","year":"2012","journal-title":"Blood"},{"key":"key20240314101459_b189-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta\/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat Biotechnol"},{"key":"key20240314101459_b190-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1182\/blood-2013-10-535245","article-title":"ICOS-based chimeric antigen receptors program bipolar TH17\/TH1 cells","volume":"124","author":"Guedan","year":"2014","journal-title":"Blood"},{"key":"key20240314101459_b191-ijo-64-04-05628","first-page":"669","article-title":"FDA approves first CAR T therapy","volume":"16","author":"Mullard","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"key20240314101459_b192-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20240314101459_b193-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"key":"key20240314101459_b194-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1172\/JCI133215","article-title":"Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability","volume":"130","author":"Guedan","year":"2020","journal-title":"J Clin Invest"},{"key":"key20240314101459_b195-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nri2887","article-title":"Mechanisms for T cell receptor triggering","volume":"11","author":"van der Merwe","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"key20240314101459_b196-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-018-0020-8","article-title":"Regulatory mechanisms in T cell receptor signalling","volume":"18","author":"Gaud","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"key20240314101459_b197-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","article-title":"Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency","volume":"25","author":"Feucht","year":"2019","journal-title":"Nat Med"},{"key":"key20240314101459_b198-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"eaan1088","DOI":"10.1126\/scisignal.aan1088","article-title":"Tuning ITAM multiplicity on T cell receptors can control potency and selectivity to ligand density","volume":"11","author":"James","year":"2018","journal-title":"Sci Signal"},{"issue":"Suppl 1","key":"key20240314101459_b199-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"S7386","DOI":"10.1182\/blood-2022-168651","article-title":"Co-Transduced CD19\/BCMA dual-targeting CAR-T cells for the treatment of non-hodgkin lymphoma","volume":"140","author":"Bachiller","year":"2022","journal-title":"Blood"},{"issue":"Suppl 1","key":"key20240314101459_b200-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"S10352","DOI":"10.1182\/blood-2022-164879","article-title":"Dual antigen targeting with co-transduced CD19\/22 CAR T cells may prevent antigen-negative relapse after CAR T cell therapy for relapsed\/refractory ALL","volume":"140","author":"Ghorashian","year":"2022","journal-title":"Blood"},{"key":"key20240314101459_b201-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1080\/14712598.2020.1790521","article-title":"CAR-T cells: The Chinese experience","volume":"20","author":"Wang","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"key20240314101459_b202-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1182\/blood-2015-12-629089","article-title":"Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies","volume":"127","author":"Sun","year":"2016","journal-title":"Blood"},{"key":"key20240314101459_b203-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1002\/cam4.1518","article-title":"Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases","volume":"7","author":"Dhupkar","year":"2018","journal-title":"Cancer Med"},{"key":"key20240314101459_b204-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat Biotechnol"},{"issue":"3 Suppl","key":"key20240314101459_b205-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/j.bbmt.2015.11.291","article-title":"Identification of PD1 and TIM3 As checkpoints that limit chimeric antigen receptor T cell efficacy in leukemia","volume":"22","author":"Kenderian","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"key20240314101459_b206-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"6713","DOI":"10.1158\/1078-0432.CCR-05-0883","article-title":"Gemcitabine selectively eliminates splenic Gr-1+\/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity","volume":"11","author":"Suzuki","year":"2005","journal-title":"Clin Cancer Res"},{"key":"key20240314101459_b207-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.4049\/jimmunol.1202781","article-title":"Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma mode","volume":"190","author":"Sevko","year":"2013","journal-title":"J Immunol"},{"key":"key20240314101459_b208-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12967-016-1037-z","article-title":"Gemcitabine reduces MDSCs, tregs and TGF\u03b2-1 while restoring the teff\/treg ratio in patients with pancreatic cancer","volume":"14","author":"Eriksson","year":"2016","journal-title":"J Transl Med"},{"key":"key20240314101459_b209-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1158\/0008-5472.CAN-09-3690","article-title":"5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity","volume":"70","author":"Vincent","year":"2010","journal-title":"Cancer Res"},{"key":"key20240314101459_b210-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"8270","DOI":"10.1158\/1078-0432.CCR-08-0165","article-title":"Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma","volume":"14","author":"Kusmartsev","year":"2008","journal-title":"Clin Cancer Res"},{"key":"key20240314101459_b211-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12885-019-6499-y","article-title":"Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells","volume":"20","author":"Yoshida","year":"2020","journal-title":"BMC Cancer"},{"key":"key20240314101459_b212-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.3337","article-title":"CSF-1R inhibition alters macrophage polarization and blocks glioma progression","volume":"19","author":"Pyonteck","year":"2013","journal-title":"Nat Med"},{"key":"key20240314101459_b213-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ccr.2013.09.014","article-title":"Low-dose irradiation programs macrophage differentiation to an iNOS+\/M1 phenotype that orchestrates effective T cell immunotherapy","volume":"24","author":"Klug","year":"2013","journal-title":"Cancer Cell"},{"key":"key20240314101459_b214-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1002\/mc.22879","article-title":"Low dose radiation primed iNOS + M1macrophages modulate angiogenic programming of tumor derived endothelium","volume":"57","author":"Nadella","year":"2018","journal-title":"Mol Carcinog"},{"key":"key20240314101459_b215-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1158\/2159-8290.CD-16-0850","article-title":"Overcoming the immunosuppressive tumor microenvironment of Hodgkin lymphoma using chimeric antigen receptor T cells","volume":"7","author":"Ruella","year":"2017","journal-title":"Cancer Discov"},{"key":"key20240314101459_b216-ijo-64-04-05628","first-page":"rs.3.rs-2709282","article-title":"Oral TGF-\u03b2R1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti-tumor immunity","author":"Choi","year":"2023","journal-title":"Res Sq"},{"key":"key20240314101459_b217-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"e133977","DOI":"10.1172\/jci.insight.133977","article-title":"TGF-\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors","volume":"5","author":"Tang","year":"2020","journal-title":"JCI Insight"},{"key":"key20240314101459_b218-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1158\/2326-6066.CIR-16-0376","article-title":"Transgenic expression of IL15 improves antiglioma activity of IL13R\u03b12-CAR T cells but results in antigen loss variants","volume":"5","author":"Krenciute","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"key20240314101459_b219-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","article-title":"IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression","volume":"71","author":"Chmielewski","year":"2011","journal-title":"Cancer Res"},{"key":"key20240314101459_b220-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"13125","DOI":"10.18632\/oncotarget.24442","article-title":"IL-21 modulates memory and exhaustion phenotype of T-cells in a fatty acid oxidation-dependent manner","volume":"9","author":"Loschinski","year":"2018","journal-title":"Oncotarget"},{"key":"key20240314101459_b221-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13045-022-01255-x","article-title":"Rewiring mitochondrial metabolism to counteract exhaustion of CAR-T cells","volume":"15","author":"Huang","year":"2022","journal-title":"J Hematol Oncol"},{"key":"key20240314101459_b222-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"4479","DOI":"10.1172\/JCI69589","article-title":"Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function","volume":"123","author":"Sukumar","year":"2013","journal-title":"J Clin Invest"},{"key":"key20240314101459_b223-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.cell.2016.09.031","article-title":"L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity","volume":"167","author":"Geiger","year":"2016","journal-title":"Cell"},{"key":"key20240314101459_b224-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.omtm.2020.07.008","article-title":"Enhancing chimeric antigen receptor T cell anti-tumor function through advanced media design","volume":"18","author":"Ghassemi","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"key20240314101459_b225-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"key20240314101459_b226-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"key":"key20240314101459_b227-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"key20240314101459_b228-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"eaau5907","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci Transl Med"},{"key":"key20240314101459_b229-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/PPO.0000000000000377","article-title":"Management of T-cell engaging immunotherapy complications","volume":"25","author":"Varadarajan","year":"2019","journal-title":"Cancer J"},{"key":"key20240314101459_b230-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S0092-8674(00)81731-6","article-title":"Tumor induction of VEGF promoter activity in stromal cells","volume":"94","author":"Fukumura","year":"1998","journal-title":"Cell"},{"key":"key20240314101459_b231-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"3953","DOI":"10.1172\/JCI43490","article-title":"Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice","volume":"120","author":"Chinnasamy","year":"2010","journal-title":"J Clin Invest"},{"key":"key20240314101459_b232-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/gt.2013.19","article-title":"Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency","volume":"20","author":"Wang","year":"2013","journal-title":"Gene Ther"},{"key":"key20240314101459_b233-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"7168","DOI":"10.1158\/0008-5472.CAN-14-2458","article-title":"Trafficking of T cells into tumors","volume":"74","author":"Slaney","year":"2014","journal-title":"Cancer Res"},{"key":"key20240314101459_b234-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1089\/humc.2013.144","article-title":"Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurre head and neck cancer","volume":"24","author":"van Schalkwyk","year":"2013","journal-title":"Hum Gene Ther Clin Dev"},{"key":"key20240314101459_b235-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3390\/cancers9070092","article-title":"Regional delivery of chimeric antigen receptor (CAR) T-cells for cancer therapy","volume":"9","author":"Sridhar","year":"2017","journal-title":"Cancers (Basel)"},{"key":"key20240314101459_b236-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nature24993","article-title":"Runx3 programs CD8(+) T cell residency in non-lymphoid tissues and tumors","volume":"552","author":"Milner","year":"2017","journal-title":"Nature"},{"key":"key20240314101459_b237-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nm.3833","article-title":"Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes","volume":"21","author":"Caruana","year":"2015","journal-title":"Nat Med"},{"key":"key20240314101459_b238-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1097\/CJI.0b013e3181ee6675","article-title":"Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b","volume":"33","author":"Craddock","year":"2010","journal-title":"J Immunother"},{"key":"key20240314101459_b239-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","article-title":"T cells expressing chimeric antigen receptors can cause anaphylaxis in humans","volume":"1","author":"Maus","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"key20240314101459_b240-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","article-title":"Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells","volume":"112","author":"Till","year":"2008","journal-title":"Blood"},{"key":"key20240314101459_b241-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s40425-017-0294-6","article-title":"Prospects for combined use of oncolytic viruses and CAR T-cells. Review","volume":"5","author":"Ajina","year":"2017","journal-title":"J Immunother Cancer"},{"key":"key20240314101459_b242-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/s41467-017-00324-x","article-title":"Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms","volume":"8","author":"Kim","year":"2017","journal-title":"Nat Commun"},{"key":"key20240314101459_b243-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1700187","DOI":"10.1002\/mabi.201700187","article-title":"Solid tumor immunotherapy with T cell engager-armed oncolytic viruses","volume":"18","author":"Scott","year":"2018","journal-title":"Macromol Biosci"},{"key":"key20240314101459_b244-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","article-title":"A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors","volume":"76","author":"Liu","year":"2016","journal-title":"Cancer Res"},{"key":"key20240314101459_b245-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1002\/acg2.84","article-title":"TRUCKS, the fourth-generation CAR T cells: Current developments and clinical translation","volume":"3","author":"Chmielewski","year":"2020","journal-title":"Adv Cell Gene Ther"},{"key":"key20240314101459_b246-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40164-020-00190-2","article-title":"Engineering better chimeric antigen receptor T cells","volume":"9","author":"Zhang","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"key20240314101459_b247-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"e12741","DOI":"10.1111\/sji.12741","article-title":"Treating osteosarcoma with CAR T cells","volume":"89","author":"K\u00f6ksal","year":"2019","journal-title":"Scand J Immunol"},{"key":"key20240314101459_b248-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"e1474318","DOI":"10.1080\/2162402X.2018.1474318","article-title":"Low-dose cyclophosphamide depletes circulating na\u00efve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy","volume":"7","author":"Noordam","year":"2018","journal-title":"Oncoimmunology"},{"key":"key20240314101459_b249-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00262-011-1106-3","article-title":"Metronomic cyclophosphamide treatment in metastasized breast cancer patients: Immunological effects and clinical outcome","volume":"61","author":"Ge","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"key20240314101459_b250-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1158\/1078-0432.CCR-17-1365","article-title":"T-cell homing therapy for reducing regulatory T cells and preserving effector T-cell function in large solid tumors","volume":"24","author":"Hu","year":"2018","journal-title":"Clin Cancer Res"},{"key":"key20240314101459_b251-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1158\/0008-5472.CAN-13-1545","article-title":"Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer","volume":"74","author":"Alizadeh","year":"2014","journal-title":"Cancer Res"},{"key":"key20240314101459_b252-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s00262-012-1293-6","article-title":"The expression, function, and clinical relevance of B7 family members in cancer","volume":"61","author":"Seliger","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"key20240314101459_b253-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/j.ymthe.2021.02.024","article-title":"Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity","volume":"29","author":"Murad","year":"2021","journal-title":"Mol Ther"},{"key":"key20240314101459_b254-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41417-021-00303-x","article-title":"Key chemokines direct migration of immune cells in solid tumors","volume":"29","author":"Kohli","year":"2022","journal-title":"Cancer Gene Ther"},{"key":"key20240314101459_b255-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ccell.2020.11.005","article-title":"Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung tumors and improves antitumor efficacy when combined with checkpoint blockade","volume":"39","author":"Srivastava","year":"2021","journal-title":"Cancer Cell"},{"key":"key20240314101459_b256-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0092-8674(00)00140-9","article-title":"Mannose 6-phosphate\/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis","volume":"103","author":"Motyka","year":"2000","journal-title":"Cell"},{"key":"key20240314101459_b257-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.1158\/0008-5472.CAN-12-2236","article-title":"Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy","volume":"72","author":"Ramakrishnan","year":"2012","journal-title":"Cancer Res"},{"key":"key20240314101459_b258-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1083\/jcb.200210150","article-title":"A clathrin\/dynaminand mannose-6-phosphate receptor-independent pathway for granzyme B-induced cell death","volume":"160","author":"Trapani","year":"2003","journal-title":"J Cell Biol"},{"key":"key20240314101459_b259-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.4049\/jimmunol.1301119","article-title":"Synergistic chemoimmunotherapy of epithelial ovarian cancer using ErbB-Retargeted T cells combined with carboplatin","volume":"191","author":"Parente-Pereira","year":"2013","journal-title":"J Immunol"},{"key":"key20240314101459_b260-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molonc.2011.11.005","article-title":"Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy","volume":"6","author":"Proietti","year":"2012","journal-title":"Mol Oncol"},{"key":"key20240314101459_b261-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1126\/science.1224922","article-title":"An immunosurveillance mechanism controls cancer cell ploidy","volume":"337","author":"Senovilla","year":"2012","journal-title":"Science"},{"key":"key20240314101459_b262-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.4161\/cc.8.22.10026","article-title":"Chemotherapy induces ATP release from tumor cells","volume":"8","author":"Martins","year":"2009","journal-title":"Cell Cycle"},{"key":"key20240314101459_b263-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"588","DOI":"10.3389\/fimmu.2015.00588","article-title":"Molecular and translational classifications of DAMPs in immunogenic cell death","volume":"6","author":"Garg","year":"2015","journal-title":"Front Immunol"},{"key":"key20240314101459_b264-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/nm.3708","article-title":"Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy","volume":"20","author":"Sistigu","year":"2014","journal-title":"Nat Med"},{"key":"key20240314101459_b265-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/1097-0215(20000715)87:2<253::AID-IJC17>3.0.CO;2-A","article-title":"Cyclophosphamide enhances anti-tumor effect of wild-type p53-specific CTL","volume":"87","author":"Vierboom","year":"2000","journal-title":"Int J Cancer"},{"key":"key20240314101459_b266-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.4161\/cbt.8.15.9133","article-title":"Enhancing immune responses to tumor-associated antigens","volume":"8","author":"Higgins","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"key20240314101459_b267-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1758834017742575","DOI":"10.1177\/1758834017742575","article-title":"Radiation effects on antitumor immune responses: Current perspectives and challenges","volume":"10","author":"Walle","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"key20240314101459_b268-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","article-title":"Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat Med"},{"key":"key20240314101459_b269-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nri3806","article-title":"Regulation of antiviral T cell responses by type I interferons","volume":"15","author":"Crouse","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"key20240314101459_b270-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1158\/0008-5472.CAN-10-2820","article-title":"The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity","volume":"71","author":"Burnette","year":"2011","journal-title":"Cancer Res"},{"key":"key20240314101459_b271-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1084\/jem.20101158","article-title":"Type I interferon is selectively required by dendritic cells for immune rejection of tumors","volume":"208","author":"Diamond","year":"2011","journal-title":"J Exp Med"},{"key":"key20240314101459_b272-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1084\/jem.20101159","article-title":"Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells","volume":"208","author":"Fuertes","year":"2011","journal-title":"J Exp Med"},{"key":"key20240314101459_b273-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1158\/0008-5472.CAN-17-1788","article-title":"NKG2D-based CAR T cells and radiotherapy exert synergistic efficacy in glioblastoma","volume":"78","author":"Weiss","year":"2018","journal-title":"Cancer Res"},{"key":"key20240314101459_b274-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.4049\/jimmunol.181.5.3099","article-title":"Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells","volume":"181","author":"Matsumura","year":"2008","journal-title":"J Immunol"},{"key":"key20240314101459_b275-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1084\/jem.20062056","article-title":"Induced sensitization of tumor stroma leads to eradication of established cancer by T cells","volume":"204","author":"Zhang","year":"2007","journal-title":"J Exp Med"},{"key":"key20240314101459_b276-ijo-64-04-05628","first-page":"1462","article-title":"Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication","volume":"62","author":"Ganss","year":"2002","journal-title":"Cancer Res"},{"key":"key20240314101459_b277-ijo-64-04-05628","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2217\/cns.12.14","article-title":"Severity, etiology and possible consequences of treatment-related lymphopenia in patients with newly diagnosed high-grade gliomas","volume":"1","author":"Yovino","year":"2012","journal-title":"CNS Oncol"}],"container-title":["International Journal of Oncology"],"original-title":[],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T08:15:41Z","timestamp":1710404141000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ijo.2024.5628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":277,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,2,22]]}},"URL":"https:\/\/doi.org\/10.3892\/ijo.2024.5628","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,22]]},"article-number":"40"}}